Conatus Pharmaceuticals Inc. (CNAT)

[micham2012]

From 3/1 PR:

“We intend to use the upcoming conferences to provide context for our four planned data readouts, the first being the announcement of top-line results from our POLT-HCV-SVR trial in the second quarter,” said Dr. Mento. “This randomized, placebo-controlled Phase 2b trial is evaluating two years of treatment with emricasan, our first-in-class pan-caspase inhibitor, in post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy.”

What exactly does this mean: "provide context" for data readouts?

I read somewhere that the trial was fully enrolled by early February 2016, and that it is likely that the trial was completed a month ago. If so, is it reasonable to think that Roth and Oppenheimer have a pretty good idea what that data is going to look like?

Any help would be appreciated.